Noster Inc.
Muko, JP· latest recorded location
Noster Inc. is named on 11 US grants and 6 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 11
- Published applications
- 6
- Inventors
- 19
- Granted in 2026 so far
- 1
- Most recent grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2020 | 1 | 1 |
| 2021 | 4 | 2 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 3 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 17 documents
- A61KMedicines and medical preparations13
- A61PTherapeutic uses of medicines11
- A23LFoods, foodstuffs or non-alcoholic beverages, not otherwise provided for9
- C12NMicroorganisms or enzymes7
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition6
- C07CAcyclic or carbocyclic compounds5
- Y02ATechnologies for adaptation to climate change4
- A23KFodder3
- C07KPeptides3
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3
Recent patents
- Anti-inflammatory agent containing rare fatty acid4 Aug 2026US 12,697,318 B2
- Metabolism-improving agent comprising rare fatty acid9 Dec 2025US 12,491,173 B2
- Production method for rare fatty acid using novel enzyme, and novel rare fatty acid19 Aug 2025US 12,391,968 B2
- Composition for inhibiting growth of bacterium having menaquinone synthesis pathway through futalosine or futalosine derivative15 Jul 2025US 12,357,601 B2
- Lipopolysaccharide-regulated enteric bacteria and use thereof22 Aug 2023US 11,730,772 B2
- Composition for inhibiting growth of bacterium having menaquinone synthesis pathway through futalosine or futalosine derivative14 Sep 2023US 2023/0285343 A1
- Bacterial supplying system17 Nov 2022US 2022/0367021 A1
- Production method for rare fatty acid using novel enzyme, and novel rare fatty acid10 Feb 2022US 2022/0042053 A1
- Method for producing rare fatty acid using novel enzyme, and novel rare fatty acid16 Sep 2021US 2021/0285020 A1
- Metabolism-improving agent comprising rare fatty acid5 Aug 2021US 2021/0236448 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.